Hi I am pleased to report that MindBio Therapeutics has completed the acquisition of Life AI Corp, a life sciences focused technology company that is developing predictive technologies for enhancing health and wellness. It's most progressive technolo...

Hi I am delighted to share a novel discovery in our clinical trials. Our engineers have developed a method to determine if a patient has dosed their medicine, simply by analysing their voice!The discovery has led to the announcement today of the acq...

MindBio Therapeutics Corp. Reports Six Month Sustained Antidepressant Response in Clinical Trials. 72% reduction in Depression Severity Recorded.Dear ,We are excited to share significant progress in our mission to transform mental health treatments....

Hi We are thrilled to share some significant progress from our ongoing Phase 2B clinical trial focused on advanced-stage cancer patients experiencing symptoms of anxiety, depression and existential distress. In this Phase 2B study, 40 participants ar...

Hi MindBio is pleased to report it has completed its 6-month milestone post treatment with MB22001 in a Phase 2A microdosing depression trial and will be releasing the data in the coming fortnight.Photo: Justin Hanka, MindBio CEO and Co-Founder insp...

Dr Rachael Sumner discusses Microdosing MB22001 for negative mood symptom relief in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

Here is the link to the clinical trial paper on Sleep produced by MindBio scientific collaborators and published in Nature’s portfolio journal Translational Psychiatry:https://www.nature.com/articles/s41398-024-02900-4

Unlocking Market Potential: Leveraging Big Data Analytics to Revolutionize Depression Research

MindBio publishes positive Phase 2a Data in Landmark Depression Trial

Positive Phase 2a results reported in Depression trial. Permalink